Cartesian Therapeutics Announces New Employment Inducement Grants

RNAC 01.07.2025

Full Press ReleaseSEC FilingsOur RNAC Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
  • 01.07.2025 - Julian Harrison
  • 01.07.2025 - Cartesian Therapeutics Announces New Employment Inducement Grants

Recent Filings

  • 01.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EFFECT Notice of Effectiveness

FREDERICK, Md.,Jan. 07, 2025(GLOBE NEWSWIRE) --Cartesian Therapeutics, Inc.(NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. OnJanuary 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of$16.93, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The option vests as to 25% onJanuary 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested onJanuary 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

AboutCartesian Therapeutics

Cartesian Therapeuticsis a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visitwww.cartesiantherapeutics.comor follow the Company onLinkedInorX, formerly known as Twitter.

Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Relationsmegan.leduc@cartesiantx.com

Media Contact:David RosenArgot Partnersdavid.rosen@argotpartners.com

Primary Logo

Source: Cartesian Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com